21
Jul
Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced. In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial. As per the…